Chushuang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chushuang Chen has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Bivard
Department of Neurology, Melbourne Brain Centre (J.L.B., H.T.J., L.C., A.H.B., C.W., B.Y., A.B., F.L., H.Z., G.A.D., S.M.D., B.C.V.C.), The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia
12 shared publications - Longting Lin
University of New South Wales South Western Sydney Clinical School
11 shared publications - Mark W. Parsons
Department of Neurology and Neurophysiology, Liverpool Hospital, Liverpool, NSW, Australia
11 shared publications Qiang Dong
9 shared publicationsLongting Lin
South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia
7 shared publicationsNeil J. Spratt
7 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2643-2652
Tenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trial
BACKGROUND: Tenecteplase has been previously evaluated in large- and medium-sized vessel occlusion subgroups, but its effectiveness in more distal occlusions, particularly those involving the distal middle cerebral artery branches or the anterior cerebral artery and posterior cerebral artery territories, and across varying ischemic core and perfusion profiles, remains uncertain. METHODS: We performed a secondary analysis of TASTE (Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation), a randomized clinical trial comparing tenecteplase and alteplase in patients presenting within 4.5 hours of symptom onset with perfusion imaging-confirmed stroke and evidence of target mismatch (penumbra/core ratio >1.8 and an absolute difference >15 mL). The primary outcome was the modified Rankin Scale (mRS) score of 0 to 1 at 90 days. We compared the effect of tenecteplase versus alteplase in subgroups based on occlusion site (proximal M2, distal M2, M3 and beyond, anterior cerebral artery, and posterior cerebral artery), ischemic core, core growth rate, and penumbra. The treatment effect of tenecteplase and alteplase was compared stratifying by the subgroup of interest, adjusting for age, baseline National Institutes of Health Stroke Scale score, and premorbid mRS score in modified Poisson regression models. RESULTS: Of the 680 patients enrolled, 492 were included in the primary analysis (median age, 73 [interquartile range, 63–82] years; male sex: 306/492 [62%]). Two hundred forty-two (49%) received tenecteplase, and 250 (51%) received alteplase. Tenecteplase was associated with a higher proportion of mRS score of 0 to 1 with distal (M3 and beyond) occlusions (tenecteplase: 62/81 [77%] versus alteplase: 59/93 [63%]; adjusted risk ratio, 1.23 [95% CI, 1.04–1.46]). Numerically higher rates of mRS score of 0 to 1 were observed with distal M2 (tenecteplase: 30/46 [65%] versus alteplase 28/48 [58%]; adjusted risk ratio, 1.14 [95% CI, 0.84–1.54]) and anterior cerebral artery occlusions (tenecteplase: 12/21 [57%] versus alteplase 5/13 [38%]; adjusted risk ratio, 1.46 [95% CI, 0.71–3.00]). No treatment differences were seen for proximal M2 or posterior cerebral artery occlusions ( P interaction across all occlusion sites: 0.89). Across ischemic core, penumbra, and core growth rate subgroups, no difference in treatment effect was observed. CONCLUSIONS: Patients with distal middle cerebral artery occlusions who are treated with tenecteplase are more likely to achieve an mRS score of 0 to 1 at 90 days than those treated with alteplase. REGISTRATION: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12613000243718.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2643-2652
Tenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trial
BACKGROUND: Tenecteplase has been previously evaluated in large- and medium-sized vessel occlusion subgroups, but its effectiveness in more distal occlusions, particularly those involving the distal middle cerebral artery branches or the anterior cerebral artery and posterior cerebral artery territories, and across varying ischemic core and perfusion profiles, remains uncertain. METHODS: We performed a secondary analysis of TASTE (Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation), a randomized clinical trial comparing tenecteplase and alteplase in patients presenting within 4.5 hours of symptom onset with perfusion imaging-confirmed stroke and evidence of target mismatch (penumbra/core ratio >1.8 and an absolute difference >15 mL). The primary outcome was the modified Rankin Scale (mRS) score of 0 to 1 at 90 days. We compared the effect of tenecteplase versus alteplase in subgroups based on occlusion site (proximal M2, distal M2, M3 and beyond, anterior cerebral artery, and posterior cerebral artery), ischemic core, core growth rate, and penumbra. The treatment effect of tenecteplase and alteplase was compared stratifying by the subgroup of interest, adjusting for age, baseline National Institutes of Health Stroke Scale score, and premorbid mRS score in modified Poisson regression models. RESULTS: Of the 680 patients enrolled, 492 were included in the primary analysis (median age, 73 [interquartile range, 63–82] years; male sex: 306/492 [62%]). Two hundred forty-two (49%) received tenecteplase, and 250 (51%) received alteplase. Tenecteplase was associated with a higher proportion of mRS score of 0 to 1 with distal (M3 and beyond) occlusions (tenecteplase: 62/81 [77%] versus alteplase: 59/93 [63%]; adjusted risk ratio, 1.23 [95% CI, 1.04–1.46]). Numerically higher rates of mRS score of 0 to 1 were observed with distal M2 (tenecteplase: 30/46 [65%] versus alteplase 28/48 [58%]; adjusted risk ratio, 1.14 [95% CI, 0.84–1.54]) and anterior cerebral artery occlusions (tenecteplase: 12/21 [57%] versus alteplase 5/13 [38%]; adjusted risk ratio, 1.46 [95% CI, 0.71–3.00]). No treatment differences were seen for proximal M2 or posterior cerebral artery occlusions ( P interaction across all occlusion sites: 0.89). Across ischemic core, penumbra, and core growth rate subgroups, no difference in treatment effect was observed. CONCLUSIONS: Patients with distal middle cerebral artery occlusions who are treated with tenecteplase are more likely to achieve an mRS score of 0 to 1 at 90 days than those treated with alteplase. REGISTRATION: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12613000243718.
- 1 December 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (12) , 3332-3341
Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial
BACKGROUND: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography. METHODS: ETERNAL-LVO (Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion) was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia. The primary outcome was the modified Rankin Scale score of 0 to 1 or return to baseline at 90 days via a modified Poisson regression model. Secondary outcomes include the modified Rankin Scale, considered as an ordinal variable, and symptomatic intracerebral hemorrhage. RESULTS: Following trial initiation, a supply shortage of the investigational product hindered recruitment. When supply resumed, phase 3 evidence had emerged supporting tenecteplase use within 4.5 hours of stroke onset, including large vessel occlusion. ETERNAL-LVO was, therefore, terminated early. Two hundred forty-two participants (median age: 73 years, 43% female, 79% undergoing EVT) were included in the modified intention-to-treat analysis; 120 received tenecteplase and 122 received standard care. No difference in the primary outcome was observed between the tenecteplase (n=44, 37%) and standard care (n=52, 43%; adjusted risk ratio, 0.90 [95% CI, 0.66–1.21]; P =0.48). No significant differences in an ordinal analysis of the modified Rankin Scale were observed between the 2 treatment groups. In a planned per-protocol analysis, the odds of improvement by 1 point in the modified Rankin Scale were doubled in the tenecteplase-treated transfer subgroup compared with standard care transfer patients (odds ratio, 2.61 [95% CI, 1.07–6.40]). Symptomatic intracerebral hemorrhage occurred in 5 (4%) participants assigned to tenecteplase and was present in 1 (1%) participant assigned to standard care. CONCLUSIONS: Treatment with tenecteplase did not increase the likelihood of a favorable functional outcome, but early stoppage of the study prevents definitive conclusions from being drawn. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04454788.
- 1 December 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (12) , 3332-3341
Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial
BACKGROUND: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography. METHODS: ETERNAL-LVO (Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion) was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia. The primary outcome was the modified Rankin Scale score of 0 to 1 or return to baseline at 90 days via a modified Poisson regression model. Secondary outcomes include the modified Rankin Scale, considered as an ordinal variable, and symptomatic intracerebral hemorrhage. RESULTS: Following trial initiation, a supply shortage of the investigational product hindered recruitment. When supply resumed, phase 3 evidence had emerged supporting tenecteplase use within 4.5 hours of stroke onset, including large vessel occlusion. ETERNAL-LVO was, therefore, terminated early. Two hundred forty-two participants (median age: 73 years, 43% female, 79% undergoing EVT) were included in the modified intention-to-treat analysis; 120 received tenecteplase and 122 received standard care. No difference in the primary outcome was observed between the tenecteplase (n=44, 37%) and standard care (n=52, 43%; adjusted risk ratio, 0.90 [95% CI, 0.66–1.21]; P =0.48). No significant differences in an ordinal analysis of the modified Rankin Scale were observed between the 2 treatment groups. In a planned per-protocol analysis, the odds of improvement by 1 point in the modified Rankin Scale were doubled in the tenecteplase-treated transfer subgroup compared with standard care transfer patients (odds ratio, 2.61 [95% CI, 1.07–6.40]). Symptomatic intracerebral hemorrhage occurred in 5 (4%) participants assigned to tenecteplase and was present in 1 (1%) participant assigned to standard care. CONCLUSIONS: Treatment with tenecteplase did not increase the likelihood of a favorable functional outcome, but early stoppage of the study prevents definitive conclusions from being drawn. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04454788.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214079
Cost-Effectiveness of Endovascular Thrombectomy in Large Vessel Occlusion Stroke for the Very Elderly
Endovascular thrombectomy (EVT) is associated with considerable clinical benefits for patients after large vessel occlusion (LVO) stroke. However, EVT remains underused in Australia, particularly among the very elderly (aged ≥80 years). The aim of this study was to evaluate the cost-effectiveness and clinical effectiveness of EVT vs standard medical management among very elderly patients using real-world, observational data. A modeled cost-effectiveness study was conducted from the Australian health care perspective. Data from a retrospective cohort of patients aged 80 years or older treated with EVT at 4 comprehensive stroke centers across Australia and New Zealand, as well as data from the International Stroke Perfusion Imaging Registry, were used to inform our economic analyses. The distribution of 90-day modified Rankin Scale (mRS) outcomes after propensity score matching was used to inform a decision-analytic Markov model. Costs and utility data for calculating quality-adjusted life years (QALYs) were drawn from published sources. The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained for EVT compared with medical management. Uncertainty was evaluated with deterministic and probabilistic sensitivity analyses. A total of 548 patients (mean age 85.1 years and 296 women [54%]) were included to inform the propensity score matching analysis. After propensity score matching, the proportion of patients with favorable (mRS score ≤2) outcomes was higher for EVT vs standard care (37% vs 18%). Based on the modeled cost-effectiveness analysis comprising a hypothetical sample of 10,000 patients, EVT was estimated to prevent 471 deaths over a period of 15 years. On a per-patient basis, EVT was associated with a gain of 0.95 years of life and 0.97 QALYs at a net cost of AU$3,399. That is, from a health care perspective, EVT is cost-effective for very elderly patients with LVO stroke (ICER: $3,508 per QALY). Sensitivity analyses supported the robustness of the model, with 100% of simulated ICERs falling below the commonly accepted Australian willingness-to-pay threshold of AU$50,000 per QALY. EVT is cost-effective and associated with considerable clinical benefits relative to standard medical management for very elderly patients with LVO stroke. Our findings support the provision of EVT to the very elderly.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214079
Cost-Effectiveness of Endovascular Thrombectomy in Large Vessel Occlusion Stroke for the Very Elderly
Endovascular thrombectomy (EVT) is associated with considerable clinical benefits for patients after large vessel occlusion (LVO) stroke. However, EVT remains underused in Australia, particularly among the very elderly (aged ≥80 years). The aim of this study was to evaluate the cost-effectiveness and clinical effectiveness of EVT vs standard medical management among very elderly patients using real-world, observational data. A modeled cost-effectiveness study was conducted from the Australian health care perspective. Data from a retrospective cohort of patients aged 80 years or older treated with EVT at 4 comprehensive stroke centers across Australia and New Zealand, as well as data from the International Stroke Perfusion Imaging Registry, were used to inform our economic analyses. The distribution of 90-day modified Rankin Scale (mRS) outcomes after propensity score matching was used to inform a decision-analytic Markov model. Costs and utility data for calculating quality-adjusted life years (QALYs) were drawn from published sources. The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained for EVT compared with medical management. Uncertainty was evaluated with deterministic and probabilistic sensitivity analyses. A total of 548 patients (mean age 85.1 years and 296 women [54%]) were included to inform the propensity score matching analysis. After propensity score matching, the proportion of patients with favorable (mRS score ≤2) outcomes was higher for EVT vs standard care (37% vs 18%). Based on the modeled cost-effectiveness analysis comprising a hypothetical sample of 10,000 patients, EVT was estimated to prevent 471 deaths over a period of 15 years. On a per-patient basis, EVT was associated with a gain of 0.95 years of life and 0.97 QALYs at a net cost of AU$3,399. That is, from a health care perspective, EVT is cost-effective for very elderly patients with LVO stroke (ICER: $3,508 per QALY). Sensitivity analyses supported the robustness of the model, with 100% of simulated ICERs falling below the commonly accepted Australian willingness-to-pay threshold of AU$50,000 per QALY. EVT is cost-effective and associated with considerable clinical benefits relative to standard medical management for very elderly patients with LVO stroke. Our findings support the provision of EVT to the very elderly.
- 1 November 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (11) , 3165-3174
Salvageable Time Window: Tissue Clock After Acute Ischemic Stroke Onset
BACKGROUND: Salvageable ischemic tissue has become the treatment target of endovascular therapy (EVT). This study proposed a new concept of salvageable time window that measures the dynamic process of salvageable tissue. We hypothesized that patients who received EVT beyond the salvageable time window would have limited benefits. METHODS: This was a retrospective multicenter study based on the INSPIRE (International Stroke Perfusion Imaging Registry), enrolling patients with acute ischemic stroke due to large vessel occlusion within 6 hours of stroke onset (August 2011–April 2022, 22 sites). Patients were divided into 3 groups: EVT delivered within the salvageable time window, EVT delivered outside the salvageable time window, and a historical no EVT control. Salvageable time window was calculated by salvageable tissue volume divided by core growth rate, which estimates the time for infarction expanding to the whole ischemic region. Patients were considered outside the window if EVT was initiated after their estimated salvageable window. The primary outcome was a good functional outcome defined by 3-month modified Rankin Scale score of 0 to 2. Propensity score matching was applied to reduce selection bias among groups. RESULTS: Overall, 1291 patients (mean age 70.3 years, 43.6% female) were included in the study, with 456 in the no EVT group, 727 in the EVT within salvageable time window group, and 108 in the EVT outside salvageable time window group. After propensity score matching (n=62 per group), patients received EVT within the salvageable time window had higher odds of good functional outcome compared with those with no EVT (48% versus 29%, odds ratio, 2.29 [95% CI, 1.09–4.81]; P =0.028), without increased risk of bleeding (type 2 parenchymal hematoma of 2% versus 3%, odds ratio, 0.49 [95% CI, 0.04–5.57]; P =0.566). In contrast, patients received EVT outside the salvageable time window did not show improved 3-month functional outcomes (32% versus 29%, odds ratio, 1.16 [95% CI, 0.54–2.50]; P =0.697) and demonstrated an increased bleeding risk (type 2 parenchymal hematoma of 17% versus 3%, odds ratio, 5.83 [95% CI, 1.22, 27.9]; P =0.027). CONCLUSIONS: This study indicates the importance of estimating the salvageable time window within 6 hours of stroke onset, as initiating endovascular treatment beyond salvageable time window may not benefit.
- 1 November 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (11) , 3165-3174
Salvageable Time Window: Tissue Clock After Acute Ischemic Stroke Onset
BACKGROUND: Salvageable ischemic tissue has become the treatment target of endovascular therapy (EVT). This study proposed a new concept of salvageable time window that measures the dynamic process of salvageable tissue. We hypothesized that patients who received EVT beyond the salvageable time window would have limited benefits. METHODS: This was a retrospective multicenter study based on the INSPIRE (International Stroke Perfusion Imaging Registry), enrolling patients with acute ischemic stroke due to large vessel occlusion within 6 hours of stroke onset (August 2011–April 2022, 22 sites). Patients were divided into 3 groups: EVT delivered within the salvageable time window, EVT delivered outside the salvageable time window, and a historical no EVT control. Salvageable time window was calculated by salvageable tissue volume divided by core growth rate, which estimates the time for infarction expanding to the whole ischemic region. Patients were considered outside the window if EVT was initiated after their estimated salvageable window. The primary outcome was a good functional outcome defined by 3-month modified Rankin Scale score of 0 to 2. Propensity score matching was applied to reduce selection bias among groups. RESULTS: Overall, 1291 patients (mean age 70.3 years, 43.6% female) were included in the study, with 456 in the no EVT group, 727 in the EVT within salvageable time window group, and 108 in the EVT outside salvageable time window group. After propensity score matching (n=62 per group), patients received EVT within the salvageable time window had higher odds of good functional outcome compared with those with no EVT (48% versus 29%, odds ratio, 2.29 [95% CI, 1.09–4.81]; P =0.028), without increased risk of bleeding (type 2 parenchymal hematoma of 2% versus 3%, odds ratio, 0.49 [95% CI, 0.04–5.57]; P =0.566). In contrast, patients received EVT outside the salvageable time window did not show improved 3-month functional outcomes (32% versus 29%, odds ratio, 1.16 [95% CI, 0.54–2.50]; P =0.697) and demonstrated an increased bleeding risk (type 2 parenchymal hematoma of 17% versus 3%, odds ratio, 5.83 [95% CI, 1.22, 27.9]; P =0.027). CONCLUSIONS: This study indicates the importance of estimating the salvageable time window within 6 hours of stroke onset, as initiating endovascular treatment beyond salvageable time window may not benefit.
- 20 February 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (6) , 687-695
Persistent penumbral profiles indicate a potentially good outcome in acute stroke patients without major reperfusion
Background: It is acknowledged that penumbra can exist beyond 24 h after stroke onset. Aims: The aim of this study was to explore the association between penumbral persistence at 24–72 h and clinical outcomes in patients who did not achieve major reperfusion. Methods: Eligible patients participating in the International Stroke Perfusion Imaging Registry with repeated 24–72 h perfusion imaging were retrospectively included in this study. Persistent penumbra was evaluated as the volume of hypoperfusion lesion on repeated perfusion imaging divided by infarct volume on the follow-up imaging at 24–72 h post arrival. Short-term clinical outcomes were defined as neurological deterioration at 24–72 h and modified Rankin Scale (mRS) 0–2 at discharge. Long-term outcome was defined as mRS 0–2 at 3 months. The association between persistent penumbra and clinical outcomes was explored using multivariable-adjusted logistic regression models. Results: A total number of 203 patients were included in this study. Persistent penumbra was associated with decreased odds of neurological deterioration at 24–72 h (multivariable-adjusted odds ratio (OR) = 0.3, 95% confidence interval (CI) = 0.1–0.8, p = 0.01) and increased odds of mRS 0–2 at 3 months (multivariable-adjusted OR = 2.7, 95% CI = 1.1–6.8, p = 0.03). Persistent penumbra was not associated with mRS 0–2 at discharge (multivariable-adjusted OR = 2.5, 95% CI = 0.4–14.7, p = 0.30). Conclusions: Persistent penumbra in acute stroke patients without major reperfusion was generally associated with a better clinical outcome. This evidence suggested that there were patients with persistent hemodynamic support, for whom major reperfusion might not be pivotal to achieve a good clinical outcome. How to identify these patients and what treatment strategy can be made to stabilize the hemodynamics need future investigation. Data access statement: Anonymized data not published within this article will be made available at the request of qualified investigators whose proposal of data use has been approved by an independent review committee.
- 20 February 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (6) , 687-695
Persistent penumbral profiles indicate a potentially good outcome in acute stroke patients without major reperfusion
Background: It is acknowledged that penumbra can exist beyond 24 h after stroke onset. Aims: The aim of this study was to explore the association between penumbral persistence at 24–72 h and clinical outcomes in patients who did not achieve major reperfusion. Methods: Eligible patients participating in the International Stroke Perfusion Imaging Registry with repeated 24–72 h perfusion imaging were retrospectively included in this study. Persistent penumbra was evaluated as the volume of hypoperfusion lesion on repeated perfusion imaging divided by infarct volume on the follow-up imaging at 24–72 h post arrival. Short-term clinical outcomes were defined as neurological deterioration at 24–72 h and modified Rankin Scale (mRS) 0–2 at discharge. Long-term outcome was defined as mRS 0–2 at 3 months. The association between persistent penumbra and clinical outcomes was explored using multivariable-adjusted logistic regression models. Results: A total number of 203 patients were included in this study. Persistent penumbra was associated with decreased odds of neurological deterioration at 24–72 h (multivariable-adjusted odds ratio (OR) = 0.3, 95% confidence interval (CI) = 0.1–0.8, p = 0.01) and increased odds of mRS 0–2 at 3 months (multivariable-adjusted OR = 2.7, 95% CI = 1.1–6.8, p = 0.03). Persistent penumbra was not associated with mRS 0–2 at discharge (multivariable-adjusted OR = 2.5, 95% CI = 0.4–14.7, p = 0.30). Conclusions: Persistent penumbra in acute stroke patients without major reperfusion was generally associated with a better clinical outcome. This evidence suggested that there were patients with persistent hemodynamic support, for whom major reperfusion might not be pivotal to achieve a good clinical outcome. How to identify these patients and what treatment strategy can be made to stabilize the hemodynamics need future investigation. Data access statement: Anonymized data not published within this article will be made available at the request of qualified investigators whose proposal of data use has been approved by an independent review committee.
- 1 February 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (2) , 488-493
Novel Vascular Territory Mapping Algorithm as a Predictive Tool for Identification of Antegrade Flow in Middle Cerebral Artery Occlusion
BACKGROUND: Vascular territory mapping (VTM) software estimates which intracerebral vessel provides predominant arterial flow to a brain voxel. The presence of antegrade flow in the setting of acute middle cerebral artery (MCA) occlusion is associated with improved outcomes. We identify whether VTM software is a determinant of antegrade flow in patients with proximal MCA occlusion. METHODS: Consecutive patients with the first branch of MCA (M1) occlusion were analyzed from the International Stroke Perfusion Imaging Registry with their computed tomography perfusion reprocessed through VTM software. Authors reviewed dynamic 4-dimensional computed tomography angiography for the presence of an acute M1 thrombus and also for the presence of residual antegrade flow. The VTM software assigned regions of the brain to an estimated feeding vessel (anterior cerebral artery, MCA, and posterior cerebral artery). A binomial logistic regression was performed to determine the effects of VTM, ischemic core (cerebral blood flow 3) on the likelihood that patients had the presence of any antegrade flow in the MCA territory. A secondary analysis was performed to assess the relationship between imaging variables and 3-month modified Rankin Scale outcomes. RESULTS: The final data set included 130 patients with M1 occlusion. The median age of participants was 74 years (interquartile range, 62–81) with an onset-to-scan time of 2.1 hours (interquartile range, 1.4–3.8) and a National Institutes of Health Stroke Scale score of 15 (interquartile range, 12–20). Eighteen patients were identified with antegrade flow on 4-dimensional digital subtraction angiography. Patients with antegrade flow had significantly larger VTM volume normal side MCA, 101 (72–180) mL, compared with those with complete occlusion, 41 (21–71) mL. VTM volume normal side MCA volume significantly predicted antegrade flow and outcome, and 1 mL VTM volume normal side MCA volume increased odds of antegrade flow by 1.024 (95% CI, 1.013–1.036). Ischemic core and the perfusion lesion volumes did not predict antegrade flow. CONCLUSIONS: VTM software was more effective than traditional perfusion parameters in the detection of antegrade flow. The results demonstrate a potential clinical utility for VTM; however, larger cohorts will be required to detect whether VTM can predict clinical outcome after reperfusion treatment.
- 1 February 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (2) , 488-493
Novel Vascular Territory Mapping Algorithm as a Predictive Tool for Identification of Antegrade Flow in Middle Cerebral Artery Occlusion
BACKGROUND: Vascular territory mapping (VTM) software estimates which intracerebral vessel provides predominant arterial flow to a brain voxel. The presence of antegrade flow in the setting of acute middle cerebral artery (MCA) occlusion is associated with improved outcomes. We identify whether VTM software is a determinant of antegrade flow in patients with proximal MCA occlusion. METHODS: Consecutive patients with the first branch of MCA (M1) occlusion were analyzed from the International Stroke Perfusion Imaging Registry with their computed tomography perfusion reprocessed through VTM software. Authors reviewed dynamic 4-dimensional computed tomography angiography for the presence of an acute M1 thrombus and also for the presence of residual antegrade flow. The VTM software assigned regions of the brain to an estimated feeding vessel (anterior cerebral artery, MCA, and posterior cerebral artery). A binomial logistic regression was performed to determine the effects of VTM, ischemic core (cerebral blood flow 3) on the likelihood that patients had the presence of any antegrade flow in the MCA territory. A secondary analysis was performed to assess the relationship between imaging variables and 3-month modified Rankin Scale outcomes. RESULTS: The final data set included 130 patients with M1 occlusion. The median age of participants was 74 years (interquartile range, 62–81) with an onset-to-scan time of 2.1 hours (interquartile range, 1.4–3.8) and a National Institutes of Health Stroke Scale score of 15 (interquartile range, 12–20). Eighteen patients were identified with antegrade flow on 4-dimensional digital subtraction angiography. Patients with antegrade flow had significantly larger VTM volume normal side MCA, 101 (72–180) mL, compared with those with complete occlusion, 41 (21–71) mL. VTM volume normal side MCA volume significantly predicted antegrade flow and outcome, and 1 mL VTM volume normal side MCA volume increased odds of antegrade flow by 1.024 (95% CI, 1.013–1.036). Ischemic core and the perfusion lesion volumes did not predict antegrade flow. CONCLUSIONS: VTM software was more effective than traditional perfusion parameters in the detection of antegrade flow. The results demonstrate a potential clinical utility for VTM; however, larger cohorts will be required to detect whether VTM can predict clinical outcome after reperfusion treatment.
- Open Access
- 1 January 2025
- Published by BMJ in BMJ Neurology Open
- Vol. 7 (1) , e001114
Time to endovascular thrombectomy for acute ischaemic stroke in language other than English (LOTE) communities in South-Western Sydney
Background: Access to endovascular thrombectomy (EVT) for acute ischaemic stroke (AIS) and the outcome disparities in culturally and linguistically diverse (CALD) populations are understudied. South-Western Sydney (SWS), characterised by high prevalence of CALD populations, provides an ideal setting to explore these disparities. This study aimed to assess whether being born in a country where English is not the primary language (‘language other than English’; LOTE) affects access to EVT and outcomes for acute ischaemic stroke while also identifying demographic risk factors influencing stroke severity and outcomes.Methods: A retrospective cohort study was conducted on consecutive patients with AIS who underwent EVT at Liverpool Hospital, Sydney, from 2018 to 2023. Participants were categorised based on country-of-origin Australia/New Zealand/United Kingdom or LOTE. Primary outcomes included time metrics—onset-to-arrival (OTA) and arrival-to-puncture (ATP)—and 3-month modified Rankin Score (mRS). Statistical analyses included multivariate logistic regression to evaluate predictors of functional outcomes.Results: Of 911 EVT referrals, 721 patients were included. LOTE patients (50.3%) were more likely to have diabetes mellitus (30% vs 16%; p<0.001) and presented with higher stroke severity (median National Institutes of Health Stroke Scale (NIHSS) 17 vs 14; p<0.001). They also experienced shorter ATP (158 vs 174 min; p=0.006). Patients requiring interpreters equally exhibited shorter ATP times (152 vs 170 min; p=0.01) and higher stroke severity. There was no significant disadvantage hailing from the LOTE group in OTA times and in any time metrics for subgroup analyses stratified by primary presenter status. However, LOTE patients had poorer 3-month outcomes (mRS ≤2: 46.5% vs 55.4%; p=0.021), which was associated with higher baseline NIHSS and diabetes in adjusted analyses.Conclusion: LOTE patients in SWS undergoing EVT were not disadvantaged in hospital time metrics. Poorer 3-month functional outcomes in LOTE patients highlight the need for targeted strategies addressing risk factors, such as diabetes mellitus.
- 1 January 2025
- Published by BMJ in BMJ Neurology Open
- Vol. 7 (1) , e001114
Open AccessTime to endovascular thrombectomy for acute ischaemic stroke in language other than English (LOTE) communities in South-Western Sydney
Background: Access to endovascular thrombectomy (EVT) for acute ischaemic stroke (AIS) and the outcome disparities in culturally and linguistically diverse (CALD) populations are understudied. South-Western Sydney (SWS), characterised by high prevalence of CALD populations, provides an ideal setting to explore these disparities. This study aimed to assess whether being born in a country where English is not the primary language (‘language other than English’; LOTE) affects access to EVT and outcomes for acute ischaemic stroke while also identifying demographic risk factors influencing stroke severity and outcomes.Methods: A retrospective cohort study was conducted on consecutive patients with AIS who underwent EVT at Liverpool Hospital, Sydney, from 2018 to 2023. Participants were categorised based on country-of-origin Australia/New Zealand/United Kingdom or LOTE. Primary outcomes included time metrics—onset-to-arrival (OTA) and arrival-to-puncture (ATP)—and 3-month modified Rankin Score (mRS). Statistical analyses included multivariate logistic regression to evaluate predictors of functional outcomes.Results: Of 911 EVT referrals, 721 patients were included. LOTE patients (50.3%) were more likely to have diabetes mellitus (30% vs 16%; p<0.001) and presented with higher stroke severity (median National Institutes of Health Stroke Scale (NIHSS) 17 vs 14; p<0.001). They also experienced shorter ATP (158 vs 174 min; p=0.006). Patients requiring interpreters equally exhibited shorter ATP times (152 vs 170 min; p=0.01) and higher stroke severity. There was no significant disadvantage hailing from the LOTE group in OTA times and in any time metrics for subgroup analyses stratified by primary presenter status. However, LOTE patients had poorer 3-month outcomes (mRS ≤2: 46.5% vs 55.4%; p=0.021), which was associated with higher baseline NIHSS and diabetes in adjusted analyses.Conclusion: LOTE patients in SWS undergoing EVT were not disadvantaged in hospital time metrics. Poorer 3-month functional outcomes in LOTE patients highlight the need for targeted strategies addressing risk factors, such as diabetes mellitus.
- Open Access
- 31 December 2024
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (3) , 367-372
Extending the time window for tenecteplase by effective reperfusion of penumbral tissue in patients with large vessel occlusion: Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 trial
Rationale: The benefit of tenecteplase in the treatment of large vessel occlusion (LVO) patients presenting within 24 h of symptom onset remains unclear. Aim: This study aimed to assess the effectiveness and safety of tenecteplase, compared to standard of care, in patients presenting within the first 24 h of symptom onset with an LVO and target mismatch on perfusion computed tomography (CT). Methods and design: The “Extending the time window for Tenecteplase by Effective Reperfusion of peNumbrAL tissue in patients with Large Vessel Occlusion” (ETERNAL-LVO) trial is a prospective, randomized, open-label, blinded-endpoint, phase 3, parallel-group, superiority trial with covariate-adjusted 1:1 randomization, and adaptive sample size re-estimation. Patients with an anterior circulation LVO stroke, who present within 24 h of stroke onset or last known well with a target mismatch on computed tomography perfusion (CTP) or magnetic resonance imaging (MRI), will be randomized to tenecteplase (0.25 mg/kg) or standard of care (alteplase 0.90 mg/kg or conservative management at clinician discretion) prior to undergoing endovascular therapy. Study outcomes: The primary outcome is the proportion of patients with a modified Rankin Scale (mRS) of 0–1 (no disability) or return to baseline mRS at 3 months. Secondary and safety outcomes include the proportion of patients with an mRS of 0–2 at 3 months, an ordinal analysis of the mRS at 3 months, the proportion of patients with symptomatic intracerebral hemorrhage (sICH), the proportion of patients with death due to any cause, and the proportion of patients with mRS 5–6 at 3 months (severe disability or death). Discussion: The ETERNAL-LVO trial will build on the current evidence for tenecteplase in the > 4.5-h window. Specifically, this trial will evaluate tenecteplase in a patient population who have access to endovascular therapy but may incur delays to endovascular therapy commencement or require transfer from a primary to a comprehensive stroke center. Trials registration: ClincialTrials.gov: NCT04454788.
- 31 December 2024
- Published by SAGE Publications in International Journal of Stroke
- Vol. 20 (3) , 367-372
Open AccessExtending the time window for tenecteplase by effective reperfusion of penumbral tissue in patients with large vessel occlusion: Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 trial
Rationale: The benefit of tenecteplase in the treatment of large vessel occlusion (LVO) patients presenting within 24 h of symptom onset remains unclear. Aim: This study aimed to assess the effectiveness and safety of tenecteplase, compared to standard of care, in patients presenting within the first 24 h of symptom onset with an LVO and target mismatch on perfusion computed tomography (CT). Methods and design: The “Extending the time window for Tenecteplase by Effective Reperfusion of peNumbrAL tissue in patients with Large Vessel Occlusion” (ETERNAL-LVO) trial is a prospective, randomized, open-label, blinded-endpoint, phase 3, parallel-group, superiority trial with covariate-adjusted 1:1 randomization, and adaptive sample size re-estimation. Patients with an anterior circulation LVO stroke, who present within 24 h of stroke onset or last known well with a target mismatch on computed tomography perfusion (CTP) or magnetic resonance imaging (MRI), will be randomized to tenecteplase (0.25 mg/kg) or standard of care (alteplase 0.90 mg/kg or conservative management at clinician discretion) prior to undergoing endovascular therapy. Study outcomes: The primary outcome is the proportion of patients with a modified Rankin Scale (mRS) of 0–1 (no disability) or return to baseline mRS at 3 months. Secondary and safety outcomes include the proportion of patients with an mRS of 0–2 at 3 months, an ordinal analysis of the mRS at 3 months, the proportion of patients with symptomatic intracerebral hemorrhage (sICH), the proportion of patients with death due to any cause, and the proportion of patients with mRS 5–6 at 3 months (severe disability or death). Discussion: The ETERNAL-LVO trial will build on the current evidence for tenecteplase in the > 4.5-h window. Specifically, this trial will evaluate tenecteplase in a patient population who have access to endovascular therapy but may incur delays to endovascular therapy commencement or require transfer from a primary to a comprehensive stroke center. Trials registration: ClincialTrials.gov: NCT04454788.
- 26 July 2024
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 44 (12) , 1593-1604
Exploring ischemic core growth rate and endovascular therapy benefit in large core patients
After stroke onset, ischemic brain tissue will progress to infarction unless blood flow is restored. Core growth rate measures the infarction speed from stroke onset. This multicenter cohort study aimed to explore whether core growth rate influences benefit from the reperfusion treatment of endovascular thrombectomy in large ischemic core stroke patients. It identified 134 patients with large core volume >70 mL assessed on brain perfusion image within 9 hours of stroke onset. Of 134 patients, 71 received endovascular thrombectomy and 63 did not receive the treatment. Overall, poor outcomes were frequent, with 3-month severed disability or death rate at 56% in treatment group and 68% in no treatment group (p = 0.156). Patients were then stratified by core growth rate. For patients with ‘ultrafast core growth’ of >70 mL/hour, rates of poor outcome were especially high in patients without endovascular thrombectomy (n = 13/14, 93%) and relatively lower in patients received the treatment (n = 12/20, 60%, p = 0.033). In contrast, for patients with core growth rate <70 mL/hour, there was not a large difference in poor outcomes between patients with and without the treatment (55% vs. 61%, p = 0.522). Therefore, patients with ‘ultrafast core growth’ might stand to benefit the most from endovascular treatment.
- 26 July 2024
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 44 (12) , 1593-1604
Exploring ischemic core growth rate and endovascular therapy benefit in large core patients
After stroke onset, ischemic brain tissue will progress to infarction unless blood flow is restored. Core growth rate measures the infarction speed from stroke onset. This multicenter cohort study aimed to explore whether core growth rate influences benefit from the reperfusion treatment of endovascular thrombectomy in large ischemic core stroke patients. It identified 134 patients with large core volume >70 mL assessed on brain perfusion image within 9 hours of stroke onset. Of 134 patients, 71 received endovascular thrombectomy and 63 did not receive the treatment. Overall, poor outcomes were frequent, with 3-month severed disability or death rate at 56% in treatment group and 68% in no treatment group (p = 0.156). Patients were then stratified by core growth rate. For patients with ‘ultrafast core growth’ of >70 mL/hour, rates of poor outcome were especially high in patients without endovascular thrombectomy (n = 13/14, 93%) and relatively lower in patients received the treatment (n = 12/20, 60%, p = 0.033). In contrast, for patients with core growth rate <70 mL/hour, there was not a large difference in poor outcomes between patients with and without the treatment (55% vs. 61%, p = 0.522). Therefore, patients with ‘ultrafast core growth’ might stand to benefit the most from endovascular treatment.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1227-1234
CTP-Defined Large Core Is a Better Predictor of Poor Outcome for Endovascular Treatment Than ASPECTS-Defined Large Core
BACKGROUND: Recent trials confirmed the effectiveness of endovascular therapy in patients with large ischemic cores. Yet the optimal neuroimaging modalities to define large core remains unclear. We tried to address this question by comparing the functional outcomes in patients receiving thrombectomy selected by either noncontrast computed tomography Alberta Stroke Program Early Computed Tomography Score (ASPECTS) or computed tomography perfusion (CTP). METHODS: This study retrospectively selected patients enrolled in the International Stroke Perfusion Registry between August 2011 and April 2022. Patients with acute stroke with large vessel occlusion in anterior circulation treated with endovascular therapy were included. All received both CTP and noncontrast computed tomography. The primary outcome was defined as poor functional outcome represented by a modified Rankin Scale score of 5 to 6 at 3 months. Large cores were defined in terms of either (1) noncontrast computed tomography ASPECTS ≤5 or (2) core volume ≥70 mL on CTP. RESULTS: A total of 1115 patients were included in the analysis, of which 90 patients had ASPECTS ≤5 (8.1%) and 97 patients CTP core ≥70 mL (8.7%). A fair agreement between ASPECTS and CTP with a κ value of 0.31 (0.21–0.40) was found. Compared with patients with neither CTP nor ASPECTS large cores, those with only ASPECTS-defined large cores (ie, ASPECTS ≤5; n=56) did not have a higher adjusted odds of poor outcome (29%; odds ratio, 1.84 [0.91–3.73]; P =0.089). However, patients with CTP large core but not ASPECTS-defined large core (n=63) had a higher adjusted odds of poor outcome (60%; odds ratio, 3.91 [2.01–7.60]; P 6 versus ≤6 hours), ASPECTS showed no discriminative difference between ≤5 and >5 in poor outcome for patients receiving endovascular therapy within 6 hours. CONCLUSIONS: CTP core ≥70 mL-defined large cores are more predictive of poor outcome than ASPECTS ≤5-defined core in endovascular therapy patients, particularly within 6 hours after stroke onset.
- 1 May 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (5) , 1227-1234
CTP-Defined Large Core Is a Better Predictor of Poor Outcome for Endovascular Treatment Than ASPECTS-Defined Large Core
BACKGROUND: Recent trials confirmed the effectiveness of endovascular therapy in patients with large ischemic cores. Yet the optimal neuroimaging modalities to define large core remains unclear. We tried to address this question by comparing the functional outcomes in patients receiving thrombectomy selected by either noncontrast computed tomography Alberta Stroke Program Early Computed Tomography Score (ASPECTS) or computed tomography perfusion (CTP). METHODS: This study retrospectively selected patients enrolled in the International Stroke Perfusion Registry between August 2011 and April 2022. Patients with acute stroke with large vessel occlusion in anterior circulation treated with endovascular therapy were included. All received both CTP and noncontrast computed tomography. The primary outcome was defined as poor functional outcome represented by a modified Rankin Scale score of 5 to 6 at 3 months. Large cores were defined in terms of either (1) noncontrast computed tomography ASPECTS ≤5 or (2) core volume ≥70 mL on CTP. RESULTS: A total of 1115 patients were included in the analysis, of which 90 patients had ASPECTS ≤5 (8.1%) and 97 patients CTP core ≥70 mL (8.7%). A fair agreement between ASPECTS and CTP with a κ value of 0.31 (0.21–0.40) was found. Compared with patients with neither CTP nor ASPECTS large cores, those with only ASPECTS-defined large cores (ie, ASPECTS ≤5; n=56) did not have a higher adjusted odds of poor outcome (29%; odds ratio, 1.84 [0.91–3.73]; P =0.089). However, patients with CTP large core but not ASPECTS-defined large core (n=63) had a higher adjusted odds of poor outcome (60%; odds ratio, 3.91 [2.01–7.60]; P 6 versus ≤6 hours), ASPECTS showed no discriminative difference between ≤5 and >5 in poor outcome for patients receiving endovascular therapy within 6 hours. CONCLUSIONS: CTP core ≥70 mL-defined large cores are more predictive of poor outcome than ASPECTS ≤5-defined core in endovascular therapy patients, particularly within 6 hours after stroke onset.